ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

NCI Selects 15 Awardees to Operate the Cancer Information Service.

January 7, 2005

Substance From Sea Squirts In Phase II For Breast Cancer

November 29, 2002

NCI Programs: Contract Awarded For Geographic Information System

May 14, 1999

ACS Encourages Research Proposals Psychosocial Aspects Of Cancer

March 26, 1982

HAI Delivery Extends Survival In Patients With Liver Metastasis

March 31, 2006